BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord 2020;45:102439. [PMID: 32769063 DOI: 10.1016/j.msard.2020.102439] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 17.5] [Reference Citation Analysis]
Number Citing Articles
1 Satyanarayan S, Safi N, Sorets T, Filomena S, Zhang Y, Klineova S, Fabian M, Horng S, Tankou S, Miller A, Krieger S, Lublin F, Sumowski J, Sand IK. Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103737] [Reference Citation Analysis]
2 Faustino P, Coutinho M, Leitão L, Capela C, Brum M, Parra J, Sequeira J, Barros A, Araújo C, Sousa A, Ladeira F. Seroconversion rate following HBV vaccination in clinical practice: The role of age and DMT treatment. Mult Scler Relat Disord 2021;50:102859. [PMID: 33652232 DOI: 10.1016/j.msard.2021.102859] [Reference Citation Analysis]
3 Ciotti JR, Perantie DC, Moss BP, Fitzgerald KC, Cohen JA, Mowry EM, Naismith RT, Chahin S. Perspectives and experiences with COVID-19 vaccines in people with MS. Multiple Sclerosis Journal - Experimental, Translational and Clinical 2022;8:205521732210852. [DOI: 10.1177/20552173221085242] [Reference Citation Analysis]
4 Bhise V, Dhib-Jalbut S. Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives. Neurotherapeutics 2021;18:244-51. [PMID: 33533012 DOI: 10.1007/s13311-021-01008-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Ye N, Cruz J, Peng X, Ma J, Zhang A, Cheng X. Remyelination is enhanced by Astragalus polysaccharides through inducing the differentiation of oligodendrocytes from neural stem cells in cuprizone model of demyelination. Brain Res 2021;1763:147459. [PMID: 33794147 DOI: 10.1016/j.brainres.2021.147459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kasarello K, Mirowska-Guzel D. Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era. Immunotargets Ther 2021;10:237-46. [PMID: 34268256 DOI: 10.2147/ITT.S240890] [Reference Citation Analysis]
7 Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, Shirbint E, Magalashvili D, Flechter S, Givon U, Guber D, Stern Y, Polliack M, Falb R, Gurevich M. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler 2021;27:864-70. [PMID: 33856242 DOI: 10.1177/13524585211003476] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 29.0] [Reference Citation Analysis]
8 Tao C, Simpson-yap S, Taylor B, Blizzard L, Lucas R, Ponsonby A, Broadley S, van der Mei I. Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103561] [Reference Citation Analysis]
9 Capone F, Lucchini M, Ferraro E, Bianco A, Rossi M, Cicia A, Cortese A, Cruciani A, De Arcangelis V, De Giglio L, Motolese F, Sancetta B, Mirabella M, Di Lazzaro V. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics 2021. [PMID: 34859382 DOI: 10.1007/s13311-021-01165-9] [Reference Citation Analysis]
10 Elsbernd PM, Carter JL. Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review. Biologics 2021;15:255-63. [PMID: 34234409 DOI: 10.2147/BTT.S267273] [Reference Citation Analysis]
11 Otero-Romero S, Sánchez-Montalvá A, Vidal-Jordana A. Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. Expert Rev Clin Immunol 2021;17:285-300. [PMID: 33543657 DOI: 10.1080/1744666X.2021.1886924] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gold R, Fätkenheuer G, Hartung HP, Kleinschnitz C, Marks R, Maschke M, Bayas A, Löbermann M, Zettl UK, Wiendl H. Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. Ther Adv Neurol Disord 2021;14:17562864211019598. [PMID: 34671422 DOI: 10.1177/17562864211019598] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sørensen PS. Editorial: Challenges in the diagnosis and treatment of multiple sclerosis. Curr Opin Neurol 2021;34:275-6. [PMID: 33935216 DOI: 10.1097/WCO.0000000000000940] [Reference Citation Analysis]
14 Klineova S, Harel A, Straus Farber R, DeAngelis T, Zhang Y, Hentz R, Leung TM, Fong K, Smith T, Blanck R, Zhovtis-Ryerson L. Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC). Mult Scler Relat Disord 2021;55:103153. [PMID: 34392059 DOI: 10.1016/j.msard.2021.103153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Winkelmann A, Loebermann M, Barnett M, Hartung HP, Zettl UK. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol 2022. [PMID: 35388213 DOI: 10.1038/s41582-022-00646-5] [Reference Citation Analysis]
16 Golshani M, Hrdý J. Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination. Vaccines 2022;10:279. [DOI: 10.3390/vaccines10020279] [Reference Citation Analysis]
17 Gyang TV, Evans JP, Miller JS, Alcorn K, Peng J, Bell EH, Zeng C, Gumina R, Liu SL, Segal BM. Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis. Mult Scler J Exp Transl Clin 2022;8:20552173221087357. [PMID: 35342640 DOI: 10.1177/20552173221087357] [Reference Citation Analysis]
18 Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines (Basel) 2021;9:99. [PMID: 33525459 DOI: 10.3390/vaccines9020099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
19 Mohseni Afshar Z, Babazadeh A, Janbakhsh A, Mansouri F, Sio TT, Sullman MJM, Carson-Chahhoud K, Hosseinzadeh R, Barary M, Ebrahimpour S. Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities. Rev Med Virol 2021;:e2309. [PMID: 34677889 DOI: 10.1002/rmv.2309] [Reference Citation Analysis]
20 Sadeghmousavi S, Rezaei N. COVID-19 and Multiple Sclerosis: Predisposition and Precautions in Treatment. SN Compr Clin Med 2020;:1-6. [PMID: 32895640 DOI: 10.1007/s42399-020-00504-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
21 Zabalza A, Arrambide G, Otero-Romero S, Pappolla A, Tagliani P, López-Maza S, Cárdenas-Robledo S, Esperalba J, Fernández-Naval C, Martínez-Gallo M, Castillo M, Bonastre M, Resina-Salles M, Bertran J, Rodriguez-Barranco M, Carbonell-Mirabent P, Gonzalez M, Merchan M, Quiroga-Varela A, Miguela A, Gómez I, Álvarez G, Robles R, Perez Del Campo D, Queralt X, Soler MJ, Agraz I, Martinez-Valle F, Rodríguez-Acevedo B, Midaglia L, Vidal-Jordana Á, Cobo-Calvo Á, Tur C, Galan I, Castillo J, Río J, Espejo C, Comabella M, Nos C, Sastre-Garriga J, Ramió-Torrentà L, Tintoré M, Montalban X. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases? Mult Scler 2022;:13524585221089540. [PMID: 35475363 DOI: 10.1177/13524585221089540] [Reference Citation Analysis]
22 Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E. Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient. Vaccines (Basel) 2021;9:1140. [PMID: 34696248 DOI: 10.3390/vaccines9101140] [Reference Citation Analysis]
23 Ozakbas S, Baba C, Dogan Y, Cevik S, Ozcelik S, Kaya E. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies. Mult Scler Relat Disord 2022;58:103486. [PMID: 35032878 DOI: 10.1016/j.msard.2022.103486] [Reference Citation Analysis]
24 Chisari CG, Toscano S, Arena S, Finocchiaro C, Montineri A, Patti F. Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. BMC Neurol 2021;21:462. [PMID: 34839814 DOI: 10.1186/s12883-021-02421-3] [Reference Citation Analysis]
25 Giossi R, Consonni A, Torri Clerici V, Zito A, Rigoni E, Antozzi C, Brambilla L, Crisafulli SG, Bellino A, Frangiamore R, Bonanno S, Vanoli F, Ciusani E, Corsini E, Andreetta F, Baggi F, Tramacere I, Mantegazza R, Conte A, Bergamaschi R, Confalonieri P. Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy. Multiple Sclerosis and Related Disorders 2021. [DOI: 10.1016/j.msard.2021.103415] [Reference Citation Analysis]
26 Yamout BI, Zakaria M, Inshasi J, Al-Jumah M, Zeineddine M, Dahdaleh M, Bohlega S, Gouider R, Alroughani R. MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. Mult Scler Relat Disord 2021;56:103225. [PMID: 34479111 DOI: 10.1016/j.msard.2021.103225] [Reference Citation Analysis]
27 Becker J, Ferreira LC, Damasceno A, Bichuetti DB, Christo PP, Callegaro D, Peixoto MAL, Sousa NAC, Almeida SM, Adoni T, Santiago-Amaral J, Junqueira T, Pereira SLA, Gomes ABAGR, Pitombeira M, Paolilo RB, Grzesiuk AK, Piccolo AC, D Almeida JAC, Gomes Neto AP, Oliveira ACP, Oliveira BS, Tauil CB, Vasconcelos CF, Kaimen-Maciel D, Varela D, Diniz DS, Oliveira EML, Malfetano FR, Borges FE, Figueira FFA, Gondim FAA, Passos GRD, Silva GD, Olival GSD, Santos GACD, Ruocco HH, Sato HK, Soares Neto HR, Cortoni Calia L, Gonçalves MVM, Vecino MCA, Pimentel MLV, Ribeiro MC, Boaventura M, Parolin MKF, Melo RBS, Lázaro R, Thomaz RB, Kleinpaul R, Dias RM, Gomes S, Lucatto SA, Alves-Leon SV, Fukuda T, Ribeiro TAGJ, Winckler TCD, Fragoso YD, Nascimento OJMD, Ferreira MLB, Mendes MF, Brum DG, Glehn FV. Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system. Arq Neuropsiquiatr 2021;79:1049-61. [PMID: 34816999 DOI: 10.1590/0004-282X-ANP-2021-0162] [Reference Citation Analysis]
28 Toscano S, Chisari CG, Patti F. Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. Neurol Ther 2021;10:627-49. [PMID: 34625925 DOI: 10.1007/s40120-021-00288-7] [Reference Citation Analysis]
29 Brill L, Rechtman A, Zveik O, Haham N, Levin N, Shifrin A, Rozenberg A, Vaknin-Dembinsky A. Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis. Mult Scler Relat Disord 2022;57:103343. [PMID: 35158452 DOI: 10.1016/j.msard.2021.103343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Sharifian-Dorche M, Sahraian MA, Fadda G, Osherov M, Sharifian-Dorche A, Karaminia M, Saveriano AW, La Piana R, Antel JP, Giacomini PS. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Mult Scler Relat Disord 2021;50:102800. [PMID: 33578206 DOI: 10.1016/j.msard.2021.102800] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
31 Gadani SP, Reyes-Mantilla M, Jank L, Harris S, Douglas M, Smith MD, Calabresi PA, Mowry EM, Fitzgerald KC, Bhargava P. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine 2021;73:103636. [PMID: 34666226 DOI: 10.1016/j.ebiom.2021.103636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Wolf A, Alvarez E. COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy. Neurol Clin Pract 2021;11:358-61. [PMID: 34484934 DOI: 10.1212/CPJ.0000000000001088] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
33 Otero-Romero S, Ascherio A, Lebrun-Frénay C. Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Curr Opin Neurol 2021;34:322-8. [PMID: 33709979 DOI: 10.1097/WCO.0000000000000929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
34 Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, Gouider R, Hacohen Y, Hellwig K, Hemmer B, Kappos L, Ladeira F, Lebrun-Frénay C, Louapre C, Magyari M, Mehling M, Oreja-Guevara C, Pandit L, Papeix C, Piehl F, Portaccio E, Ruiz-Camps I, Selmaj K, Simpson-Yap S, Siva A, Sorensen PS, Sormani MP, Trojano M, Vaknin-Dembinsky A, Vukusic S, Weinshenker B, Wiendl H, Winkelmann A, Zuluaga Rodas MI, Tintoré M, Stankoff B. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Mult Scler 2022;:13524585211069068. [PMID: 35196927 DOI: 10.1177/13524585211069068] [Reference Citation Analysis]
35 Bagnato F, Wallin M. COVID-19 Vaccine in Veterans with Multiple Sclerosis: Protect the Vulnerable. Fed Pract 2021;38:S28-32. [PMID: 34177237 DOI: 10.12788/fp.0113] [Reference Citation Analysis]
36 Smith TE, Kister I. Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies. Curr Neurol Neurosci Rep 2021;21:36. [PMID: 34009478 DOI: 10.1007/s11910-021-01117-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Cabreira V, Abreu P, Soares-Dos-Reis R, Guimarães J, Sá MJ. Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations. Vaccines (Basel) 2021;9:773. [PMID: 34358189 DOI: 10.3390/vaccines9070773] [Reference Citation Analysis]
38 Doneddu PE, Spina E, Briani C, Fabrizi GM, Manganelli F, Nobile-Orazio E; Italian Peripheral Nervous System Association (ASNP). Acute and chronic inflammatory neuropathies and COVID-19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP). J Peripher Nerv Syst 2021;26:148-54. [PMID: 33620123 DOI: 10.1111/jns.12435] [Reference Citation Analysis]
39 Solmaz I, Anlar B. Immunization in multiple sclerosis and other childhood immune-mediated disorders of the central nervous system: A review of the literature. Eur J Paediatr Neurol 2021;33:125-34. [PMID: 34214824 DOI: 10.1016/j.ejpn.2021.06.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Cobo-Calvo A, Zabalza A, Río J, Arrambide G, Otero-Romero S, Tagliani P, Cárdenas-Robledo S, Castillo M, Espejo C, Rodriguez M, Carbonell P, Rodríguez B, Midaglia L, Vidal-Jordana Á, Tur C, Galan I, Castillo J, Comabella M, Nos C, Auger C, Tintoré M, Rovira À, Montalban X, Sastre-Garriga J. Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. J Neurol 2022. [PMID: 35001198 DOI: 10.1007/s00415-021-10958-z] [Reference Citation Analysis]
41 Riccardo BA, Giulio V, Massimiliano C, Giovanna L, Valentina T, Paola C, Teresa MG, Diana F, Viviana N, Marta R, Chiara BM, Damiano P, Alberto G, Pietro A, Federica P, Massimiliano DF, Cinzia C, Emanuela Z, Riccardo S, Ivan G, Antonio S, Martina P, Marcello A, Vincenzo BM, Claudio S, Claudio G, Eleonora C, Marcello M, Roberta L; Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. J Neurol 2022. [PMID: 35165767 DOI: 10.1007/s00415-022-11009-x] [Reference Citation Analysis]
42 Dewanjee S, Vallamkondu J, Kalra RS, Puvvada N, Kandimalla R, Reddy PH. Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic. Mol Neurobiol 2021. [PMID: 34169443 DOI: 10.1007/s12035-021-02450-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Podury S, Khan E, Tandon M, Jaiswal S, Sriwastava S. Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination. J Clin Neurosci 2021;90:132-4. [PMID: 34275536 DOI: 10.1016/j.jocn.2021.05.063] [Reference Citation Analysis]
44 Li J, Liu HH, Yin XD, Li CC, Wang J. COVID-19 illness and autoimmune diseases: recent insights. Inflamm Res 2021;70:407-28. [PMID: 33640999 DOI: 10.1007/s00011-021-01446-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Landtblom AM, Berntsson SG, Boström I, Iacobaeus E. Multiple sclerosis and COVID-19: The Swedish experience. Acta Neurol Scand 2021;144:229-35. [PMID: 34028810 DOI: 10.1111/ane.13453] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
46 Sabatino JJ, Mittl K, Rowles W, Mcpolin K, Rajan JV, Zamecnik CR, Dandekar R, Alvarenga BD, Loudermilk RP, Gerungan C, Spencer CM, Sagan SA, Augusto DG, Alexander J, Hollenbach JA, Wilson MR, Zamvil SS, Bove R. Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity. medRxiv 2021:2021. [PMID: 34580672 DOI: 10.1101/2021.09.10.21262933] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Goss AL, Samudralwar RD, Das RR, Nath A. ANA Investigates: Neurological Complications of COVID-19 Vaccines. Ann Neurol 2021;89:856-7. [PMID: 33710649 DOI: 10.1002/ana.26065] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 19.0] [Reference Citation Analysis]
48 Negahdaripour M, Shafiekhani M, Moezzi SMI, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol 2021;99:108021. [PMID: 34352567 DOI: 10.1016/j.intimp.2021.108021] [Reference Citation Analysis]
49 Langhorst SE, Frahm N, Hecker M, Mashhadiakbar P, Streckenbach B, Baldt J, Heidler F, Zettl UK. Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis. JPM 2022;12:677. [DOI: 10.3390/jpm12050677] [Reference Citation Analysis]
50 Jones JM, Faruqi AJ, Sullivan JK, Calabrese C, Calabrese LH. COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review. Pathog Immun 2021;6:76-103. [PMID: 34056149 DOI: 10.20411/pai.v6i1.435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
51 Ziello A, Scavone C, Di Battista ME, Salvatore S, Di Giulio Cesare D, Moreggia O, Allegorico L, Sagnelli A, Barbato S, Manzo V, Capuano A, Maniscalco GT. Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study. Brain Sci 2021;11:890. [PMID: 34356125 DOI: 10.3390/brainsci11070890] [Reference Citation Analysis]
52 Santoro JD, Saucier LE, Tanna R, Wiegand SE, Pagarkar D, Tempchin AF, Khoshnood M, Ahsan N, Van Haren K. Inadequate Vaccine Responses in Children With Multiple Sclerosis. Front Pediatr 2021;9:790159. [PMID: 34926358 DOI: 10.3389/fped.2021.790159] [Reference Citation Analysis]
53 Khanna A, Jones GB. Envisioning Post-pandemic Digital Neurological, Psychiatric and Mental Health Care. Front Digit Health 2021;3:803315. [PMID: 34993505 DOI: 10.3389/fdgth.2021.803315] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Cencioni MT, Genchi A, Brittain G, de Silva TI, Sharrack B, Snowden JA, Alexander T, Greco R, Muraro PA. Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party. Front Immunol 2021;12:813957. [PMID: 35178046 DOI: 10.3389/fimmu.2021.813957] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
55 Tornatore C, Wiendl H, Lublin AL, Geertsen SS, Chavin J, Truffinet P, Bar-or A. Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide. Front Neurol 2022;13:828616. [DOI: 10.3389/fneur.2022.828616] [Reference Citation Analysis]
56 Moser T, Seiberl M, Feige J, Bieler L, Radlberger RF, O'Sullivan C, Pilz G, Harrer A, Schwenker K, Haschke-Becher E, Machegger L, Grimm J, Redlberger-Fritz M, Buchmann A, Khalil M, Kvas E, Trinka E, Wipfler P. Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients. Front Immunol 2021;12:718895. [PMID: 34512642 DOI: 10.3389/fimmu.2021.718895] [Reference Citation Analysis]
57 Pitzalis M, Idda ML, Lodde V, Loizedda A, Lobina M, Zoledziewska M, Virdis F, Delogu G, Pirinu F, Marini MG, Mingoia M, Frau J, Lorefice L, Fronza M, Carmagnini D, Carta E, Orrù V, Uzzau S, Solla P, Loi F, Devoto M, Steri M, Fiorillo E, Floris M, Zarbo IR, Cocco E, Cucca F. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients. Front Immunol 2021;12:781843. [PMID: 34956211 DOI: 10.3389/fimmu.2021.781843] [Reference Citation Analysis]
58 Woopen C, Schleußner K, Akgün K, Ziemssen T. Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Front Immunol 2021;12:701752. [PMID: 34234787 DOI: 10.3389/fimmu.2021.701752] [Cited by in F6Publishing: 1] [Reference Citation Analysis]